Discovering The Potential of LRRC32 as A Drug Target (G2615)

Target Name: LRRC32

NCBI ID: G2615

LRRC32

Discovering The Potential of LRRC32 as A Drug Target

LRRC32, also known as leucine-rich repeat-containing protein 32, is a protein that is found in various cell types in the human body. It is characterized by the presence of a unique repeat sequence, known as a leucine-rich repeat, which is found in the protein's N-terminus.

The study of LRRC32 has led to the discovery of its potential as a drug target. LRRC32 has been shown to play a role in a variety of cellular processes, including cell signaling, DNA replication, and stress response. Additionally, LRRC32 has been linked to a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key reasons for the potential of LRRC32 as a drug target is its unique structure. The leucine-rich repeat is a highly conserved sequence that is found in a variety of proteins, but it is not found in any other protein that has been studied as extensively as LRRC32. This makes it an attractive target for drug development because it is unlikely to have been previously identified as a drug by researchers.

Additionally, the function of LRRC32 is not well understood, which can make it an attractive target for drug development. The studies have shown that LRRC32 plays a role in a variety of cellular processes, including cell signaling, DNA replication, and stress response. This makes it an attractive target for drugs that are designed to modulate these processes.

Another reason for the potential of LRRC32 as a drug target is its association with a number of diseases. LRRC32 has been linked to a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This makes it an attractive target for drugs that are designed to treat these conditions.

The potential of LRRC32 as a drug target is still being explored and validated. However, the studies that have been conducted to date are promising and suggest that LRRC32 may be a valuable drug target. Further research is needed to fully understand the function of LRRC32 and its potential as a drug.

Protein Name: Leucine Rich Repeat Containing 32

Functions: Key regulator of transforming growth factor beta (TGFB1, TGFB2 and TGFB3) that controls TGF-beta activation by maintaining it in a latent state during storage in extracellular space (PubMed:19750484, PubMed:19651619, PubMed:22278742). Associates specifically via disulfide bonds with the Latency-associated peptide (LAP), which is the regulatory chain of TGF-beta, and regulates integrin-dependent activation of TGF-beta (PubMed:22278742). Able to outcompete LTBP1 for binding to LAP regulatory chain of TGF-beta (PubMed:22278742). Controls activation of TGF-beta-1 (TGFB1) on the surface of activated regulatory T-cells (Tregs) (PubMed:19750484, PubMed:19651619). Required for epithelial fusion during palate development by regulating activation of TGF-beta-3 (TGFB3) (By similarity)

The "LRRC32 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRC32 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets